Microsoft MAI-DxO Tops Generalist Doctors 83% to 36% in Science
Microsoft's MAI-DxO diagnosed 83.2% of hard NEJM cases vs 36.1% for generalists in a peer-reviewed Science study. It was a simulation, not live clinical use.
Artificial intelligence is moving deeper into clinical practice, from diagnostic imaging tools to generative systems that draft notes or suggest treatment pathways. As adoption accelerates, the rules governing how these tools are built, tested, and deployed are struggling to keep pace, making healthcare AI regulation one of the most consequential and fast-moving stories in health tech today.
The core tension is straightforward: AI systems increasingly influence life-and-death decisions, yet the regulatory frameworks meant to ensure their safety were largely designed for traditional medical devices with fixed functions. Machine learning models can update, drift, or behave unpredictably in ways static hardware never did, forcing agencies to rethink oversight mechanisms, approval pathways, and post-market monitoring. At the same time, individual states are stepping in with their own rules, creating a patchwork of requirements that developers and health systems must navigate alongside federal standards.
This hub tracks how regulators, lawmakers, and industry players are responding to these challenges. Readers will find coverage of federal agency actions and policy shifts, state-level legislative efforts, and the compliance hurdles facing companies that build AI-powered diagnostic and clinical tools. Coverage also extends to debates over data ownership and access, since the quality and governance of health data underpin how safely and fairly these systems perform. Expect ongoing reporting on new approval frameworks, enforcement actions, industry pushback, and the broader question of how to balance innovation with patient safety as AI becomes embedded in everyday medical care.
Microsoft's MAI-DxO diagnosed 83.2% of hard NEJM cases vs 36.1% for generalists in a peer-reviewed Science study. It was a simulation, not live clinical use.
Microsoft's MAI-DxO hit 83% on hard NEJM cases vs 36% for generalist doctors in a Science paper, but it's untested on patients and FDA rules are unclear.
Microsoft's MAI-DxO diagnosed 83% of complex NEJM cases vs 36% for generalist doctors in a Science study. It was a text-only benchmark, not a clinical trial.
A Science study found Microsoft's MAI-DxO diagnosed hard cases with 83% accuracy vs 36% for generalist doctors. Hospital trials come next, but FDA rules lag.
A new systematic review finds US hospital AI is outpacing oversight, citing four gaps from weak post-market monitoring to unclear liability.
FDA AI device list tops 1,600 entries, mostly radiology, and the agency kept 510(k) review for imaging AI, while hospitals now carry most clinical AI oversight.
With FDA's AI device list above 1,600, experts say hospitals must test clinical AI inside real workflows, monitor it after launch and rehearse outage plans.
Northwestern Medicine embedded OpenEvidence's AI evidence tool in Epic on Oct. 8, giving nurses and pharmacists access as FDA rules leave such tools unreviewed.
Kaiser, Cleveland Clinic, HCA and Mayo lead hospital AI as the FDA's AI device list reaches 1,614, 76% in radiology, and January rules loosen oversight.
A multicenter study in European Radiology finds DeepHealth's FDA-cleared Prostate AI, combined with radiologist MRI reads, could avoid 18.9% of biopsies while
Microsoft's MAI-DxO diagnosed 83% of hard cases vs 36% for generalist doctors in a Science study, as FDA weighs rules for generative AI devices.
A Science study found OpenAI's o1 beat two internists at diagnosing 76 real ER patients (67% vs. 50–55%), while FDA rules for such tools remain unsettled.
Microsoft's MAI-DxO scored 83% vs 36% for generalist doctors in a Science study and moves to a Boston hospital trial, though no generative AI diagnostic has
The FDA asked for public comment on regulating generative AI medical devices through October 19, 2026, but it left hospital monitoring capacity unresolved.
Hospitals are scaling AI scribes and imaging platforms as the FDA's AI device list hits 1,614 and looser CDS rules shift vetting onto health systems.
xAID published its own ranking of seven AI radiology platforms for teleradiology groups and placed itself first, ahead of Aidoc, Viz.ai, Rad AI and Qure.ai.
Imaging AI shows trial-backed accuracy gains and FDA counts exceed 1,600 devices, while chatbots lag and new guidance shifts AI vetting to hospitals.
The FDA has now authorized over 1,600 AI medical devices, 76% of them in radiology. Hospitals use AI widely, but fewer than 20% use it well for core diagnosis.
Health systems signed enterprise AI deals in 2026 as FDA-listed AI devices hit 1,614, mostly radiology, and new FDA guidance eased decision-support oversight.
A Northwell study of 3,856 brain CT scans found Aidoc's FDA-cleared AI flagged 55 aneurysms radiologists missed, a 39% gain, but fell short in outpatient care.
FDA AI device clearances have topped 1,000, but research shows hospitals are adopting AI faster than evidence and governance can keep pace.
A Harvard-led Science study finds AI beat doctors on diagnosis and ER triage tasks, fueling debate over regulation and clinical readiness.
FDA opened public comment on regulating generative AI medical devices, proposing risk tiers and doctor-style competency testing by Oct. 19, 2026.
BioGen AI's MedSense claims to outdiagnose doctors, fueling debate over AI's expanding, loosely regulated role in hospitals.
Intermountain Medical Center becomes the second US hospital to deploy an AI-enhanced MRI machine that speeds scans and sharpens images.
Democrats sign an AI regulation pledge as the FDA seeks feedback on AI medical devices amid mental health AI lawsuits and healthcare ROI debates.
A Pennsylvania lawsuit and new FDA feedback push highlight gaps in mental health AI oversight and trust.
FDA's 2026 guidance exempts more AI decision tools from review as Harvard and Nature studies show AI matching doctors, shifting validation to hospitals.
AI radiology tools promise faster reports amid a radiologist shortage, but FDA oversight and outcome data still lag behind adoption.
AI's rapid healthcare adoption faces scrutiny after a Mayo Clinic lawsuit alleges a 67% diagnostic error rate, raising oversight concerns.